Skip to Content


Active Substance: pancreas powder
Common Name: pancreas powder
ATC Code: A09AA02
Marketing Authorisation Holder: Allergan Pharmaceuticals International Ltd
Active Substance: pancreas powder
Status: Withdrawn
Authorisation Date: 2016-06-29
Therapeutic Area: Exocrine Pancreatic Insufficiency
Pharmacotherapeutic Group: Digestives, incl. enzymes

Therapeutic Indication

Pancreatic enzyme replacement treatment in exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (e.g. chronic pancreatitis, post pancreatectomy or pancreatic cancer).
Enzepi is indicated in infants, children, adolescents and adults.

The marketing authorisation for Enzepi has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.